Koyfin Home > Directory > Health Care > Amphastar Pharma > Capital Expenditures

Amphastar Pharma Capital Expenditures Chart (AMPH)

Amphastar Pharma annual/quarterly Capital Expenditures from 2014 to 2018.
  • Amphastar Pharma Capital Expenditures for the quarter ending September 09, 2018 was $-13m a 19.92% decrease of -3m year over year
  • Amphastar Pharma Capital Expenditures for the last 12 months ending September 09, 2018 was $-47m a 25.86% decrease of -12m year over year
  • Amphastar Pharma Annual Capital Expenditures for 2017 was $-35m a 39.08% decrease of -14m from 2016
  • Amphastar Pharma Annual Capital Expenditures for 2016 was $-21m a 25.19% decrease of -5m from 2015
  • Amphastar Pharma Annual Capital Expenditures for 2015 was $-16m a -28.15% increase of 5m from 2014
Other Cash Flow Metrics:
  • Amphastar Pharma Cash Flow from Operations for the quarter ending September 09, 2018 was $16m a 38.12% increase of 6m year over year
  • Amphastar Pharma Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $2m a 389.71% increase of 8m year over year
  • Amphastar Pharma Total Revenue for the quarter ending December 12, 2018 was $90m a 34.89% increase of 31m year over year
View Chart On Koyfin

Quarterly AMPH Capital Expenditures Data

09/2018$-13m
06/2018$-12m
03/2018$-12m
12/2017$-10m
09/2017$-10m
06/2017$-7m
03/2017$-7m
12/2016$-5m
09/2016$-3m
06/2016$-8m

Annual AMPH Capital Expenditures Data

2017$-35m
2016$-21m
2015$-16m
2014$-20m
2013$-18m